SGP · Spyglass Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · SGP
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $8.54M | - | - | - |
| SG&A | $6.87M | - | - | - |
| Total Operating Expenses | $7.42M | - | - | - |
| D&A | $318.0K | - | - | - |
| Operating Income | ($15.41M) | - | - | - |
| Interest Expense | - | - | - | - |
| Income Tax | $0 | - | - | - |
| Net Income | ($8.82M) | - | - | - |
| EPS - Basic | ($3.96) | - | - | - |
| EPS - Diluted | ($3.96) | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Cash & Equivalents | $238.90M | $96.36M | $16.27M | $15.85M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $3.51M | $2.70M | $1.98M | - |
| Current Assets | $253.36M | $108.77M | $17.41M | - |
| Total Assets | $258.39M | $115.87M | $23.32M | - |
| Current Liabilities | $6.67M | $8.58M | $7.79M | - |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $8.27M | $10.17M | $11.25M | - |
| Stockholders' Equity | $250.11M | ($98.84M) | ($60.47M) | ($32.98M) |
| Retained Earnings | ($118.55M) | ($104.73M) | ($64.86M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Operating Cash Flow | ($8.20M) | - | - | - |
| Investing Cash Flow | ($1.67M) | - | - | - |
| Financing Cash Flow | $50.10M | - | - | - |
| CapEx | $676.0K | - | - | - |
| Free Cash Flow | ($8.88M) | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | 1.01 | - | - | - |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -3.4% | - | - | - |
| Return on equity | -3.5% | - | - | - |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 38.00 | 12.67 | 2.23 | - |
| Quick ratio | 38.00 | 12.67 | 2.23 | - |
| Cash ratio | 35.83 | 11.23 | 2.09 | - |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | - | - | - |
| Equity multiplier | 1.03 | -1.17 | -0.39 | - |
| Liabilities / Assets | 0.03 | 0.09 | 0.48 | - |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | 0.2x | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - |
| Net income growth (YoY) | - | - | - | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | - | -63.4% | -83.3% | - |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing SpyGlass Pharma against the 5 most active filers in the same SIC group.